Financial Results (Quarter Ended June 30, 2026)
The Board approved the unaudited financial results for the quarter ended June 30, 2026:
- Revenue from Operations: ₹314.53 lakh (compared to ₹305.54 lakh in previous quarter and ₹540.05 lakh in year-ago quarter)
- Other Income: ₹3.63 lakh (compared to ₹21.86 lakh in previous quarter and ₹9.11 lakh in year-ago quarter)
- Total Income: ₹318.16 lakh (compared to ₹327.40 lakh in previous quarter and ₹549.16 lakh in year-ago quarter)
- Total Expenses: ₹288.14 lakh (compared to ₹299.51 lakh in previous quarter and ₹510.43 lakh in year-ago quarter)
- Profit Before Tax: ₹30.02 lakh (compared to ₹27.89 lakh in previous quarter and ₹38.73 lakh in year-ago quarter)
- Tax Expense: ₹7.00 lakh (Current Tax)
- Net Profit: ₹23.02 lakh (compared to ₹17.74 lakh in previous quarter and ₹30.23 lakh in year-ago quarter)
- Earnings Per Share (Basic & Diluted): ₹0.77 (compared to ₹0.59 in previous quarter and ₹1.01 in year-ago quarter)
- Paid-Up Equity Share Capital: ₹299.03 lakh with face value of ₹10.00 per share
The results were reviewed by the Audit Committee and Statutory Auditors (Jaymin Shah & Associates) who issued a limited review report confirming compliance with accounting standards and SEBI regulations.
Corporate Governance Matters
1. Director Re-appointment: Based on Nomination and Remuneration Committee recommendation, the Board approved the re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non-Executive Non-Independent Director post attaining age 75 years. The appointment is subject to shareholder approval. Mrs. Agrawal is a promoter with over 30 years of business experience in chemicals and electrical equipment, and is the spouse of Managing Director Mr. Jagdish Agrawal.
2. AGM Notice Amendment: The Board approved amendments to the notice for convening the 33rd Annual General Meeting.
3. CFO Remuneration: Based on Audit Committee evaluation and Nomination and Remuneration Committee recommendation, the Board accepted the revised remuneration proposal for Mr. Sumit Agrawal, Chief Financial Officer.
Operational Update
Manufacturing Facility Upgrade: The Board discussed the ongoing upgradation project for compliance with Revised Schedule M requirements:
- Construction of new warehouse block completed
- Civil work ongoing for extension of existing buildings
- Expenditure to date: ₹435 lakh on renovation and new construction
- Capital contracts/orders issued: ₹565 lakh for utilities and equipment
- Company is negotiating with banks to raise funds for project financing
Meeting Details
The Board meeting commenced at 02:30 PM and concluded at 03:25 PM on August 08, 2026.
Compliance Notes
The financial results are Ind AS compliant and fall within a single business segment of "Pharmaceutical Business." Previous quarter amounts have been re-grouped/re-classified for comparability. Results are available on the company website (www.ishitadrugs.com) and BSE website.